0000899243-20-025750.txt : 20200918 0000899243-20-025750.hdr.sgml : 20200918 20200918182502 ACCESSION NUMBER: 0000899243-20-025750 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200916 FILED AS OF DATE: 20200918 DATE AS OF CHANGE: 20200918 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: El-Hibri Fuad CENTRAL INDEX KEY: 0001380185 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 201184925 MAIL ADDRESS: STREET 1: 2273 RESEARCH BLVD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-16 0 0001367644 Emergent BioSolutions Inc. EBS 0001380185 El-Hibri Fuad 400 PROFESSIONAL DRIVE, SUITE 400 GAITHERSBURG MD 20879 1 1 1 0 Chairman Common Stock 2020-09-16 4 S 0 20000 102.48 D 1169523 D Common Stock 2020-09-17 4 S 0 20000 100.68 D 1149523 D Common Stock 2140463 I By Intervac, L.L.C. Common Stock 1524155 I By Biovac, L.L.C. The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.13 to $102.27. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.07 to $102.18. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Intervac is the direct owner of 2,140,463 shares of the Issuer's common stock. The Reporting Person serves as the managing member of Intervac and the Reporting Person or his wife serve as the trustee of each of the members of Intervac. The Reporting Person disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein. The Reporting Person, individually, and the Reporting Person and his wife, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. The Reporting Person disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein. /s/ Carl A. Valenstein, attorney-in-fact 2020-09-18